{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:05:44Z","timestamp":1793387144791,"version":"4.5.0"},"reference-count":62,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CorMedix Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Catheter-related bloodstream infections are common in patients receiving hemodialysis through a central venous catheter. Taurolidine, a novel broad-spectrum antimicrobial catheter lock solution, is FDA-approved in combination with heparin for reducing the incidence of such infections. Methods: In vitro activity of taurolidine was assessed against 442 bacterial and 50 yeast clinical bloodstream infection isolates selected from the SENTRY Antimicrobial Surveillance Program and tested according to the Clinical and Laboratory Standards Institute methodology. Multidrug-resistant species and phenotypes were included. Results: Taurolidine was highly active against all isolates, with MIC50\/MIC90 values of \u22641024\/1024 \u03bcg\/mL for most species. The highest MICs observed were among isolates of Mycobacterium avium complex and Burkholderia cepacia complex (MIC90, 2048 \u03bcg\/mL) and Candida albicans (MIC90, 4096 \u03bcg\/mL). All isolates were inhibited by 13,500 \u03bcg\/mL of taurolidine, the concentration of the commercially available product. Conclusions: Taurolidine activity was very similar among Gram-positive, Gram-negative, and yeast clinical isolates, with the activity of taurolidine being unaffected by phenotypic resistance to other antimicrobials. Taken together with clinical efficacy data from clinical trials, this provides a theoretical basis for the idea that taurolidine-based lock solutions may be able to reduce the risk of catheter-related bloodstream infections from a wide variety of pathogens and resistance phenotypes.<\/jats:p>","DOI":"10.3390\/antibiotics15080785","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:04:01Z","timestamp":1786698241000},"page":"785","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In Vitro Antimicrobial Activity of Taurolidine Against Isolates Associated with Catheter-Related Bloodstream Infections"],"prefix":"10.3390","volume":"15","author":[{"given":"Jared L.","family":"Crandon","sequence":"first","affiliation":[{"name":"CorMedix Therapeutics, Parsippany, NJ 07054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Tan","sequence":"additional","affiliation":[{"name":"CorMedix Therapeutics, Parsippany, NJ 07054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6798-7653","authenticated-orcid":false,"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories), North Liberty, IA 52317, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":false,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories), North Liberty, IA 52317, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5961-6238","authenticated-orcid":false,"given":"S. J. Ryan","family":"Arends","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories), North Liberty, IA 52317, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"ref_1","unstructured":"United States Renal Data System (2024). 2024 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1001\/jama.2024.16338","article-title":"Dialysis for Chronic Kidney Failure: A Review","volume":"332","author":"Flythe","year":"2024","journal-title":"JAMA"},{"key":"ref_3","unstructured":"CorMedix Therapeutics (2024). DefenCath [Package Insert], CorMedix Inc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2672.1980.tb05210.x","article-title":"The Relationship Between Structure and Activity of Taurolin","volume":"48","author":"Myers","year":"1980","journal-title":"J. Appl. Bacteriol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Caruso, F., Darnowski, J.W., Opazo, C., Goldberg, A., Kishore, N., Agoston, E.S., and Rossi, M. (2010). Taurolidine Antiadhesive Properties on Interaction with E. coli: Its Transformation in Biological Environment and Interaction with Bacteria Cell Wall. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0008927"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1097\/MJT.0000000000001736","article-title":"Taurolidine and Heparin as Catheter Lock Solution for Central Venous Catheters in Hemodialysis","volume":"31","author":"Nguyen","year":"2024","journal-title":"Am. J. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2215\/CJN.0000000000000278","article-title":"Taurolidine\/Heparin Lock Solution and Catheter-Related Bloodstream Infection in Hemodialysis: A Randomized, Double-Blind, Active-Control, Phase 3 Study","volume":"18","author":"Agarwal","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2215\/CJN.11411116","article-title":"National Healthcare Safety Network (NHSN) Dialysis Event Surveillance Report for 2014","volume":"12","author":"Nguyen","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2215\/CJN.0000000000000476","article-title":"A Six-Year Follow-Up of Bloodstream Infections in Hemodialysis Facilities in the United States, National Healthcare Safety Network, 2020","volume":"19","author":"Keenan","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/AAC.44.6.1720-1724.2000","article-title":"Activities of Taurolidine In Vitro and in Experimental Enterococcal Endocarditis","volume":"44","author":"Souli","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.clnu.2012.11.014","article-title":"Absence of Microbial Adaptation to Taurolidine in Patients on Home Parenteral Nutrition Who Develop Catheter-Related Bloodstream Infections and Use Taurolidine Locks","volume":"32","author":"Olthof","year":"2013","journal-title":"Clin. Nutr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10096-017-3157-7","article-title":"Postmarketing Experience with Neutrolin (Taurolidine, Heparin, Calcium Citrate) Catheter Lock Solution in Hemodialysis Patients","volume":"37","author":"Reidenberg","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Liu, Y., Zhang, A.Q., Cao, L., Xia, H.T., and Ma, J.J. (2013). Taurolidine Lock Solutions for the Prevention of Catheter-Related Bloodstream Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079417"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Sun, Y., Wan, G., and Liang, L. (2020). Taurolidine Lock Solution for Catheter-Related Bloodstream Infections in Pediatric Patients: A Meta-Analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0231110"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1177\/11297298251409615","article-title":"Efficacy of Catheter Lock Solutions on Central-Line-Associated Bloodstream Infections (CLABSI) Prevention: A Systematic Review and Bayesian Network Meta-Analysis","volume":"27","author":"Liu","year":"2025","journal-title":"J. Vasc. Access"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2019.12.001","article-title":"KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update","volume":"75","author":"Lok","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: A Prioritisation Study to Guide Research, Development, and Public Health Strategies Against Antimicrobial Resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/cid\/ciad100","article-title":"Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results from a Nationwide Study in Italy (ALARICO Network)","volume":"76","author":"Falcone","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global Guideline for the Diagnosis and Management of Candidiasis: An Initiative of the ECMM in Cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1564","DOI":"10.1016\/S2214-109X(25)00221-9","article-title":"Profile of Central Line-Associated Bloodstream Infections in Adult, Paediatric, and Neonatal Intensive Care Units of Hospitals Participating in a Health-Care-Associated Infection Surveillance Network in India: A 7-Year Multicentric Study","volume":"13","author":"Parveen","year":"2025","journal-title":"Lancet Glob. Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000178454","article-title":"In-vitro-Wirksamkeit von Taurolidin und 9 Antibiotika gegen klinische Isolate aus chirurgischem Einsendegut sowie gegen Pilze","volume":"10","author":"Focht","year":"1994","journal-title":"Chir. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e00381-24","DOI":"10.1128\/aac.00381-24","article-title":"In Vitro Activity of Taurolidine Against Clinical Candida auris Isolates: Relevance to Catheter-Related Bloodstream Infections","volume":"68","author":"Reidenberg","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","first-page":"26","article-title":"Antifungal Activity of Taurolidine Against Mucorales: An In Vitro Study on Clinical Isolates","volume":"8","author":"Jafarian","year":"2022","journal-title":"Curr. Med. Mycol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1749-8090-8-180","article-title":"Results of Surgery for Chronic Pulmonary Aspergillosis, Optimal Antifungal Therapy and Proposed High Risk Factors for Recurrence\u2014A National Centre\u2019s Experience","volume":"8","author":"Farid","year":"2013","journal-title":"J. Cardiothorac. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5301\/jva.5000168","article-title":"Efficacy of Taurolidine on the Prevention of Catheter-Related Bloodstream Infections in Patients on Home Parenteral Nutrition","volume":"14","author":"Sarveswaran","year":"2013","journal-title":"J. Vasc. Access"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clnu.2009.12.005","article-title":"Taurolidine Lock Is Highly Effective in Preventing Catheter-Related Bloodstream Infections in Patients on Home Parenteral Nutrition: A Heparin-Controlled Prospective Trial","volume":"29","author":"Bisseling","year":"2010","journal-title":"Clin. Nutr."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Olthof, E.D., Versleijen, M.W., Waal, G.H., Feuth, T., Kievit, W., and Wanten, G.J.A. (2014). Taurolidine Lock Is Superior to Heparin Lock in the Prevention of Catheter-Related Bloodstream Infections and Occlusions. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0111216"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3945\/ajcn.117.158964","article-title":"Taurolidine-Citrate-Heparin Lock Reduces Catheter-Related Bloodstream Infections in Intestinal Failure Patients Dependent on Home Parenteral Support: A Randomized, Placebo-Controlled Trial","volume":"106","author":"Tribler","year":"2017","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ling, G., Ben-Shimol, S., Elamour, S., Nassar, R., Kristal, E., Shalev, R., Howard, G., Yerushalmi, B., Kogan, S., and Shmueli, M. (2024). The Effectiveness of Taurolidine Antimicrobial Locks in Preventing Catheter-Related Bloodstream Infections (CRBSIs) in Children Receiving Parenteral Nutrition: A Case Series. Antibiotics, 13.","DOI":"10.3390\/antibiotics13090847"},{"key":"ref_33","first-page":"e90797","article-title":"The Use of Taurolidine as an Adjunctive Treatment to Reduce Recurrent Peritonitis in Peritoneal Dialysis Patients","volume":"17","author":"Argentino","year":"2025","journal-title":"Cureus"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1129729820937099","article-title":"Relapsing Peritonitis and Taurolidine Peritoneal Catheter Lock: One Center Experience","volume":"22","author":"Trapero","year":"2021","journal-title":"J. Vasc. Access"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/pbc.24482","article-title":"Central Venous Catheters and Catheter Locks in Children with Cancer: A Prospective Randomized Trial of Taurolidine Versus Heparin","volume":"60","author":"Handrup","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jhin.2012.01.003","article-title":"Randomized Controlled Trial of Taurolidine Citrate Versus Heparin as Catheter Lock Solution in Paediatric Patients with Haematological Malignancies","volume":"80","author":"Seeger","year":"2012","journal-title":"J. Hosp. Infect."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e01521-19","DOI":"10.1128\/AAC.01521-19","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients","volume":"64","author":"Gudiol","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000470911","article-title":"Taurolidine\/Citrate Lock Therapy for Primary Prevention of Catheter-Related Infections in Cancer Patients: Results of a Prospective, Randomized, Phase IV Trial (ATAPAC)","volume":"93","author":"Longo","year":"2017","journal-title":"Oncology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jhin.2024.06.009","article-title":"The CATERPILLAR Study: An Assessor-Blinded Randomized Controlled Trial Comparing a Taurolidine-Citrate-Heparin Lock Solution to a Heparin-Only Lock Solution for the Prevention of Central-Line-Associated Bloodstream Infections in Paediatric Oncology Patients","volume":"152","author":"Loeffen","year":"2024","journal-title":"J. Hosp. Infect."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"euad306","DOI":"10.1093\/europace\/euad306","article-title":"Use of a Taurolidine Containing Antimicrobial Wash to Reduce Cardiac Implantable Electronic Device Infection","volume":"25","author":"Borov","year":"2023","journal-title":"Europace"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/519177","article-title":"Risk Factors for Burkholderia cepacia Complex Bacteremia Among Intensive Care Unit Patients Without Cystic Fibrosis: A Case-Control Study","volume":"28","author":"Bressler","year":"2007","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/hdi.13021","article-title":"Reduction in Hemodialysis Catheter-Related Bloodstream Infections After Implementation of a Novel Care Program","volume":"26","author":"Lee","year":"2022","journal-title":"Hemodial. Int."},{"key":"ref_43","first-page":"848","article-title":"Outbreak of Stenotrophomonas maltophilia and Burkholderia cepacia Bloodstream Infections at a Hemodialysis Center","volume":"104","author":"Cavalcanti","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"102843","DOI":"10.1016\/j.jiph.2025.102843","article-title":"Burkholderia cepacia ST 767 Causing a Three-Year Nosocomial Outbreak in a Hemodialysis Unit","volume":"18","author":"Dantas","year":"2025","journal-title":"J. Infect. Public Health"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"ofac058","DOI":"10.1093\/ofid\/ofac058","article-title":"Waterborne Outbreaks in Hemodialysis Patients and Infection Prevention","volume":"9","author":"Kanamori","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.ajkd.2016.09.022","article-title":"Hemodialyzer Reuse and Gram-Negative Bloodstream Infections","volume":"69","author":"Edens","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An Official ATS\/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijid.2020.05.079","article-title":"Nontuberculous Mycobacterial Bloodstream Infections After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"97","author":"Nagata","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccm.2014.11.002","article-title":"Nontuberculous Mycobacteria Infections in Immunosuppressed Hosts","volume":"36","author":"Henkle","year":"2015","journal-title":"Clin. Chest Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.amjms.2015.12.012","article-title":"Epidemiology of Rapidly Growing Mycobacteria Bloodstream Infections","volume":"351","author":"Chirca","year":"2016","journal-title":"Am. J. Med. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1097\/INF.0000000000003473","article-title":"Nontuberculous Mycobacteria Blood Stream Infection in Pediatric and Adult Patients: 15 Years Surveillance","volume":"41","author":"Hussein","year":"2022","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100288","DOI":"10.1016\/j.jctube.2021.100288","article-title":"Bloodstream Infections with Rapidly Growing Nontuberculous Mycobacteria","volume":"25","author":"Comba","year":"2021","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"106039","DOI":"10.1016\/j.ekir.2026.106039","article-title":"Silent Invaders: A Case Series of CRBSI Caused by Non-Tuberculous Mycobacteria in Hemodialysis Patients","volume":"11","author":"Lalwani","year":"2026","journal-title":"Kidney Int. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1016\/j.ekir.2022.07.139","article-title":"POS-121 Hemodialysis Catheter Related Infection Caused by Mycobacterium abscessus in a Young Patient","volume":"7","author":"Hernandez","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Kadota, N., Ishikawa, K., Kubono, Y., Konishi, K., Fujimaru, T., Ito, Y., Nagahama, M., Taki, F., Kawai, F., and Mori, N. (2024). Systematic Literature Review of the Diagnosis, Prognosis, and Treatment of Peritoneal Dialysis-Related Infection Caused by Nontuberculous Mycobacteria. BMC Nephrol., 25.","DOI":"10.1186\/s12882-024-03841-2"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Lu, J., Jiang, Z., Wang, L., Mou, S., and Yan, H. (2021). Mycobacterium avium-Related Peritonitis in a Patient Undergoing Peritoneal Dialysis: Case Report and Review of the Literature. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02544-2"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1128\/AAC.46.6.1674-1679.2002","article-title":"Antimicrobial Activity of a Novel Catheter Lock Solution","volume":"46","author":"Shah","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.anaerobe.2014.11.008","article-title":"In Vitro Activity of Taurolidine on Single Species and a Multispecies Population Associated with Periodontitis","volume":"32","author":"Zollinger","year":"2015","journal-title":"Anaerobe"},{"key":"ref_59","first-page":"322","article-title":"Taurolidine: In Vitro Activity Against Multiple-Antibiotic-Resistant, Nosocomially Significant Clinical Isolates of Staphylococcus aureus, Enterococcus faecium, and Diverse Enterobacteriaceae","volume":"39","author":"Traub","year":"1993","journal-title":"Chemotherapy"},{"key":"ref_60","unstructured":"Clinical and Laboratory Standards Institute (2025). Performance Standards for Antimicrobial Susceptibility Testing, CLSI. [35th ed.]. CLSI Supplement M100."},{"key":"ref_61","unstructured":"Clinical and Laboratory Standards Institute (2018). Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes, CLSI. [3rd ed.]. CLSI Supplement M24."},{"key":"ref_62","unstructured":"Clinical and Laboratory Standards Institute (2017). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, CLSI. [4th ed.]. CLSI Supplement M27."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/8\/785\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:25:23Z","timestamp":1786699523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/8\/785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["antibiotics15080785"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15080785","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}